ASX - By Stock
|
ACR |
Re:
Ann: Launch of Dapsone 5%, Gel in the United States
|
|
Gavbo
|
44 |
13K |
3 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
44
|
13K
|
3
|
|
ASX - By Stock
|
ACR |
Re:
Ann: FY23 Results Webinar
|
|
Gavbo
|
12 |
4.9K |
2 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
12
|
4.9K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Gavbo
|
15 |
5.8K |
4 |
11/05/23 |
11/05/23 |
ASX - By Stock
|
15
|
5.8K
|
4
|
|
ASX - By Stock
|
ACR |
Re:
Investor Call
|
|
Gavbo
|
18 |
4.9K |
0 |
25/08/16 |
25/08/16 |
ASX - By Stock
|
18
|
4.9K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
Morningstar valuation
|
|
Gavbo
|
48 |
14K |
2 |
23/02/16 |
23/02/16 |
ASX - By Stock
|
48
|
14K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
Quarterly results - Predictions
|
|
Gavbo
|
17 |
4.4K |
0 |
17/10/15 |
17/10/15 |
ASX - By Stock
|
17
|
4.4K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
Quarterly results - Predictions
|
|
Gavbo
|
17 |
4.4K |
0 |
15/10/15 |
15/10/15 |
ASX - By Stock
|
17
|
4.4K
|
0
|
|
ASX - By Stock
|
ACR |
Injectable Testosterone Tied To Higher MI, Stroke Risk Than Gels
|
|
Gavbo
|
1 |
715 |
4 |
15/05/15 |
15/05/15 |
ASX - By Stock
|
1
|
715
|
4
|
|
ASX - By Stock
|
ACR |
Re:
Bounce time imminent!
|
|
Gavbo
|
212 |
79K |
2 |
01/05/15 |
01/05/15 |
ASX - By Stock
|
212
|
79K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
Looming Axiron net sales results for Q1 - 2015
|
|
Gavbo
|
64 |
26K |
2 |
24/04/15 |
24/04/15 |
ASX - By Stock
|
64
|
26K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
Acrux management - ARE YOU LISTENING?
|
|
Gavbo
|
10 |
4.6K |
0 |
19/03/15 |
19/03/15 |
ASX - By Stock
|
10
|
4.6K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
International Sales of Axiron
|
|
Gavbo
|
8 |
2.8K |
4 |
18/03/15 |
18/03/15 |
ASX - By Stock
|
8
|
2.8K
|
4
|
|
ASX - By Stock
|
ACR |
Re:
International Sales of Axiron
|
|
Gavbo
|
8 |
2.8K |
2 |
18/03/15 |
18/03/15 |
ASX - By Stock
|
8
|
2.8K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
International Sales of Axiron
|
|
Gavbo
|
8 |
2.8K |
2 |
18/03/15 |
18/03/15 |
ASX - By Stock
|
8
|
2.8K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
International Sales of Axiron
|
|
Gavbo
|
8 |
2.8K |
3 |
18/03/15 |
18/03/15 |
ASX - By Stock
|
8
|
2.8K
|
3
|
|
ASX - By Stock
|
FME |
Re:
Ann: Half Yearly Report and Accounts
|
|
Gavbo
|
1 |
871 |
0 |
18/03/15 |
18/03/15 |
ASX - By Stock
|
1
|
871
|
0
|
|
ASX - By Stock
|
ACR |
Re:
EvaMist
|
|
Gavbo
|
3 |
2.3K |
0 |
11/03/15 |
11/03/15 |
ASX - By Stock
|
3
|
2.3K
|
0
|
|
ASX - By Stock
|
ACR |
EvaMist
|
|
Gavbo
|
3 |
2.3K |
0 |
11/03/15 |
11/03/15 |
ASX - By Stock
|
3
|
2.3K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Change in substantial holding
|
|
Gavbo
|
4 |
2.2K |
2 |
11/03/15 |
11/03/15 |
ASX - By Stock
|
4
|
2.2K
|
2
|
|
ASX - By Stock
|
ACR |
ENDO 2015
|
|
Gavbo
|
0 |
381 |
1 |
10/03/15 |
10/03/15 |
ASX - By Stock
|
0
|
381
|
1
|
|
ASX - By Stock
|
ACR |
Re:
ACR - Breakout of Support
|
|
Gavbo
|
8 |
2.9K |
0 |
10/03/15 |
10/03/15 |
ASX - By Stock
|
8
|
2.9K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
Morningstar
|
|
Gavbo
|
3 |
2.5K |
0 |
06/03/15 |
06/03/15 |
ASX - By Stock
|
3
|
2.5K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
TP dropped to $0.58
|
|
Gavbo
|
28 |
9.1K |
5 |
05/03/15 |
05/03/15 |
ASX - By Stock
|
28
|
9.1K
|
5
|
|
ASX - By Stock
|
ACR |
Re:
At what $ would s T/O be attractive?
|
|
Gavbo
|
9 |
3.2K |
0 |
05/03/15 |
05/03/15 |
ASX - By Stock
|
9
|
3.2K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
TP dropped to $0.58
|
|
Gavbo
|
28 |
9.1K |
3 |
05/03/15 |
05/03/15 |
ASX - By Stock
|
28
|
9.1K
|
3
|
|
ASX - By Stock
|
ACR |
Re:
At what $ would s T/O be attractive?
|
|
Gavbo
|
9 |
3.2K |
0 |
05/03/15 |
05/03/15 |
ASX - By Stock
|
9
|
3.2K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
TP dropped to $0.58
|
|
Gavbo
|
28 |
9.1K |
0 |
05/03/15 |
05/03/15 |
ASX - By Stock
|
28
|
9.1K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
TP dropped to $0.58
|
|
Gavbo
|
28 |
9.1K |
0 |
05/03/15 |
05/03/15 |
ASX - By Stock
|
28
|
9.1K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
TP dropped to $0.58
|
|
Gavbo
|
28 |
9.1K |
2 |
05/03/15 |
05/03/15 |
ASX - By Stock
|
28
|
9.1K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
FDA Drug Safety Communication
|
|
Gavbo
|
27 |
7.7K |
2 |
04/03/15 |
04/03/15 |
ASX - By Stock
|
27
|
7.7K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
Sales would drop lots with fearful labeling
|
|
Gavbo
|
8 |
3.0K |
4 |
04/03/15 |
04/03/15 |
ASX - By Stock
|
8
|
3.0K
|
4
|
|
ASX - By Stock
|
ACR |
Re:
FDA Drug Safety Communication
|
|
Gavbo
|
27 |
7.7K |
4 |
04/03/15 |
04/03/15 |
ASX - By Stock
|
27
|
7.7K
|
4
|
|
ASX - By Stock
|
ACR |
FDA Drug Safety Communication
|
|
Gavbo
|
27 |
7.7K |
3 |
04/03/15 |
04/03/15 |
ASX - By Stock
|
27
|
7.7K
|
3
|
|
ASX - By Stock
|
ACR |
Simon Marais
|
|
Gavbo
|
1 |
1.2K |
1 |
27/02/15 |
27/02/15 |
ASX - By Stock
|
1
|
1.2K
|
1
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Half-Year Results Presentation - 31 December 2014
|
|
Gavbo
|
32 |
10K |
2 |
26/02/15 |
26/02/15 |
ASX - By Stock
|
32
|
10K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Half-Year Results Presentation - 31 December 2014
|
|
Gavbo
|
32 |
10K |
2 |
26/02/15 |
26/02/15 |
ASX - By Stock
|
32
|
10K
|
2
|
|
Charts
|
ACR |
Re:
Chart ACR
|
|
Gavbo
|
16 |
6.1K |
1 |
25/02/15 |
25/02/15 |
Charts
|
16
|
6.1K
|
1
|
|
ASX - By Stock
|
ACR |
Re:
au dollar down 20%, acr should be up
|
|
Gavbo
|
10 |
4.4K |
3 |
18/02/15 |
18/02/15 |
ASX - By Stock
|
10
|
4.4K
|
3
|
|
ASX - By Stock
|
ACR |
Re:
Why testosterone is the drug of the future
|
|
Gavbo
|
8 |
3.0K |
5 |
05/02/15 |
05/02/15 |
ASX - By Stock
|
8
|
3.0K
|
5
|
|
ASX - By Stock
|
ACR |
Why testosterone is the drug of the future
|
|
Gavbo
|
8 |
3.0K |
2 |
05/02/15 |
05/02/15 |
ASX - By Stock
|
8
|
3.0K
|
2
|
|
ASX - By Stock
|
ACR |
Re:
Quarterly Results
|
|
Gavbo
|
3 |
1.7K |
1 |
31/01/15 |
31/01/15 |
ASX - By Stock
|
3
|
1.7K
|
1
|
|
ASX - By Stock
|
ACR |
Mayo Clinic
|
|
Gavbo
|
0 |
442 |
2 |
30/01/15 |
30/01/15 |
ASX - By Stock
|
0
|
442
|
2
|
|
ASX - By Stock
|
ACR |
Re:
Low testosterone levels & stroke?
|
|
Gavbo
|
5 |
1.9K |
1 |
30/01/15 |
30/01/15 |
ASX - By Stock
|
5
|
1.9K
|
1
|
|
ASX - By Stock
|
ACR |
Re:
ACR Volume
|
|
Gavbo
|
13 |
6.0K |
0 |
18/12/14 |
18/12/14 |
ASX - By Stock
|
13
|
6.0K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
ACR Volume
|
|
Gavbo
|
13 |
6.0K |
5 |
18/12/14 |
18/12/14 |
ASX - By Stock
|
13
|
6.0K
|
5
|
|
ASX - By Stock
|
ACR |
Re:
Ann: Lilly and Acrux file lawsuit against Amneal
|
|
Gavbo
|
12 |
3.9K |
0 |
11/12/14 |
11/12/14 |
ASX - By Stock
|
12
|
3.9K
|
0
|
|
ASX - By Stock
|
ACR |
Re:
Bernstein Liebhard Lawsuit
|
|
Gavbo
|
9 |
2.2K |
1 |
10/12/14 |
10/12/14 |
ASX - By Stock
|
9
|
2.2K
|
1
|
|
ASX - By Stock
|
ACR |
Re:
Bernstein Liebhard Lawsuit
|
|
Gavbo
|
9 |
2.2K |
2 |
10/12/14 |
10/12/14 |
ASX - By Stock
|
9
|
2.2K
|
2
|
|
ASX - By Stock
|
FME |
Re:
Ann: Quarterly Reports
|
|
Gavbo
|
3 |
1.0K |
0 |
04/12/14 |
04/12/14 |
ASX - By Stock
|
3
|
1.0K
|
0
|
|
ASX - By Stock
|
FME |
Re:
Ann: Quarterly Reports
|
|
Gavbo
|
3 |
1.0K |
0 |
03/12/14 |
03/12/14 |
ASX - By Stock
|
3
|
1.0K
|
0
|
|